Monica Shah

Monica Shah, Ph.D.

Patent Agent

Monica Mann, Ph.D. joined Parker Highlander after completing a Biomedical Science graduate program at the University of Texas Health Science Center in the area of cancer biology and a post-doctoral fellowship at MD Anderson Cancer Center. Prior to her graduate studies, Monica obtained a B.S. in Biochemistry at Case Western Reserve University. During her graduate program, Monica worked in the area of understanding the mechanism of resistance to hormonal therapy in breast cancer and developing methods to overcome this resistance. Since joining Parker Highlander, Monica has focused on patentability searches, freedom-to-operate analyses, and biotechnology patent prosecution.

Areas of Concentration

  • Biotechnology and Pharmaceuticals
  • Stem Cell Biology
  • Biologics and Antibodies

Experience

Monica received her Ph.D. at the University of Texas Health Science Center at San Antonio in Biomedical Sciences, particularly focusing on Cancer Biology. Her research focused on epigenetics in breast cancer and identifying novel targets for overcoming resistance to hormonal therapy. Since joining Parker Highlander, Monica has gained experience in drafting patent applications and performing patentability analyses.

Professional Honors and Awards

  • 07/2012 Endowed Student Scholarship, The University of Texas Health Science Center at San Antonio, TX
  • 04/2012 Outstanding Oral Presentation, First Prize, Cancer Prevention Research Institute of Texas Annual Trainee Retreat, The University of Texas Health Science Center at San Antonio, TX
  • 04/2012 High Rated Poster, American Association of Cancer Research Annual Conference, IL
  • 08/2009 Dean’s Excellence Award, The University of Texas Health Science Center at San Antonio, TX
  • 2004-2008 Trustee’s Scholarship, Case Western Reserve University, OH

Publications

  • Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Gorbunova V, Jasin M, Brann D, Tekmal RR and Vadlamudi RK. Proline, Glutamic acid, Leucine rich Protein 1 (PELP1) is essential for optimal p53-mediated DNA damage response. Nature Cell Death and Differentiation, 2014.
  • Mann M, Zou Y, Chen Y, Brann D and Vadlamudi RK. PELP1 oncogene functions involve alternative splicing through PRMT6. Molecular Oncology, 2014.
  • Mann M, Cortez V and Vadlamudi RK. PELP1 oncogenic functions involve regulation of CARM1. Carcinogenesis, 2013.
  • Cortez V, Mann M, Tekmal S, Suzuki S, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK and Vadlamudi RK. Targeting PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Research, 14:R108, 2012.
  • Mann M, Krishnan S and Vadlamudi RK. Emerging Significance of Estrogen Receptor Coregulator Signaling in Breast Cancer. Minerva Ginecologica, 2012. (review)
  • Soibam B, Mann M, Liu L, Tran J, Gunaratne G, Pletcher S and Roman G. Open Field Arena Boundary is a Primary Object of Exploration for Drosophila. Brain and Behavior. 2012.
  • Mann M, Cortez V and Vadlamudi RK. Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers. 2011; 3: 1691-1707. (review)
  • Cortez V, Mann M, Brann DW and Vadlamudi RK. Extranuclear signaling by estrogen: role in breast cancer progression and metastasis. Minerva Ginecologica, 2010; 62(6): 573-83. (review)

Education

  • 2013 Ph.D. Cancer Biology UTHSCSA
  • May 2008 Bachelors of Biochemistry Case Western Reserve University

The Team